Printer Friendly

CRISPR Therapeutics signs license agreement with KSQ Therapeutics.

M2 EQUITYBITES-October 17, 2019-CRISPR Therapeutics signs license agreement with KSQ Therapeutics


Switzerland-based CRISPR Therapeutics has signed a license agreement with United States-based KSQ Therapeutics to advance their respective cell therapy programmes in oncology, it was reported yesterday.

The contract enables CRISPR, a gene editing company, to receive access to the KSQ Therapeutics' intellectual property for editing certain gene targets in its allogeneic oncology cell therapy programmes. In turn, KSQ Therapeutics will receive access to CRISPR Therapeutics' intellectual property for editing gene targets identified by it as part of its present and future engineered tumour infiltrating lymphocyte cell programmes.

Neither company revealed the financial terms of the deal.

((Comments on this story may be sent to

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Oct 17, 2019
Previous Article:Wheels raises USD50m in oversubscribed funding round.
Next Article:Brentwood Associates to divest Marshall Retail Group for undisclosed sum.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters